Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mehta Analysis: What Do Facebook Libra And Democrats At Presidential Debates Have In Common?

Executive Summary

Viren Mehta of Mehta Partners LLC mulls the potential of blockchain, the rapidly evolving IT resource that secures every step in a business action.

You may also be interested in...



Mehta Analysis: Welcome to BioPharma 2.0

Viren Mehta of Mehta Partners LLC ponders what the approval of Novartis gene therapy Zolgensma foreshadows, in terms of future therapies and pricing.

Mehta Analysis: The Promise Of 2021

Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.

Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish

As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC125532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel